INTRODUCTION

Mild cognitive impairment (MCI) is the intermediate stage between normal aging and dementia. Individuals with MCI show annual conversion rates to probable Alzheimer’s disease (AD) of approximately 10%–13% per year, while the rate in normal elderly people is 1%–2%. It has been reported that MCI with high amyloid retention had 67%–82% conversion rates to AD during 2–3 years of follow-up. However, these studies evaluated only baseline amyloid burden which could not assess serial amyloid changes during the clinical follow-up period. Subsequently, a few follow-up studies have evaluated both serial amyloid burden changes and MCI conversion to AD. Although their follow-up duration was a maximum of 5.7 years, the included baseline MCI individuals were less than 50 in number (minimum was 10). Moreover, they did not compare amyloid burden interval changes with baseline amyloid burden for the prediction of MCI conversion to AD.

Therefore, our study aimed to compare baseline amyloid burden and longitudinal amyloid burden changes in the prediction of MCI to AD.
METHODS

Participants

Seventy-five individuals with MCI were recruited from the community and from the Dementia Clinic, Chosun University Hospital, Gwangju, South Korea from April 2017 to January 2021. All subjects were fully informed about study participation, and written informed consent was obtained from all participants. All participants were examined by clinical interview, which included an assessment of the Clinical Dementia Rating (CDR).10 The participants received a CDR score of 0.5 and met Petersen’s criteria,11 which includes: 1) memory complaint corroborated by an informant, 2) objective cognitive impairment of age, education and sex, 3) essentially preserved general cognitive function, 4) largely intact functional activities, and 5) not demented. For criterion 2), a z-score performance for at least one of the attention, memory, language, visuospatial function, and frontal/executive cognitive function tests included in the Seoul Neuropsychological Screening Battery (SNSB) was below -1.5 according to the respective age-, education- and sex-specific norms. Individuals with MCI were classified as either amnestic MCI (aMCI) or nonamnestic MCI (naMCI) by including neuropsychological memory test impairments in addition to MCI diagnostic criteria.

The exclusion criteria included any current serious medical, psychiatric, or neurological disorder affecting the patient’s cognitive function, evidence of focal brain lesions on MRI including multiple lacunes and white matter hyperintensities (WMH) of grade 2 or more on the Fazekas scale;12 presence of severe behavioral or communication difficulties; or a current use of psychoactive medication.

The Institutional Review Board of Chosun University Hospital approved the study protocol (CHOSUN 2016-12-011-003).

Clinical and neuropsychological assessments

All participants were examined annually by a clinical interview. Their medical history, including stroke or family history of dementia, was also assessed. Clinical diagnoses including CDR scores, were made after reviewing all available information in consensus case conferences (authors of IHC, AC, JYC, JMH, HK). MCI converters were defined when the follow-up diagnosis was AD following National Institute on Aging–Alzheimer’s Association diagnostic criteria.13 MCI non-converters were defined when the follow-up diagnosis was not AD including reversion to cognitively normal and MCI again. A comprehensive neuropsychological assessment was also performed annually using the SNSB II,14 which covers five cognitive domains. The attention domain was assessed using a forward and backward digit span test. The language domain was assessed using a shortened form of the Korean version of the Boston Naming Test (BNT, 15-item version, Form A). The visuospatial domain was assessed using the copying test from the Rey Complex Figure Test (RCFT). The memory domain was assessed by six measures: the Seoul Verbal Learning Test (SVLT) immediate recall (SVLTrcl), SVLT 20-minute delayed recall (SVLTrdl), SVLTS yes-no recognition (SVLTrcg), RCFT immediate recall (RCFTrcl), RCFT 20-minute delayed recall (RCFTrdl), and RCFT yes-no recognition (RCFTrcg). The frontal/executive domain was assessed by category fluency tests (animal and supermarket lists), Stroop test (Stroop_W, word reading; Stroop_CW, color naming in the color-word incongruent condition), and Trail Making Tests A and B. Global cognition was assessed using the Mini-Mental State Examination.

Image acquisition

T1-weighted 3D volumes were acquired (3T, Siemens AVANTO) for co-registration with positron emission tomography (PET) and to define the region of interest (ROI). Additionally, fluid-attenuated inversion recovery images were obtained for WMH readings.

PET scans were performed using a PET/CT scanner (Discovery ST PET/CT, GE) with a field of view of 250 mm, providing slices of 3.3 mm thickness and 256×256 matrix size. The brain 3D acquisition mode was used. Images were reconstructed from the data with ordered-subset expectation maximum iterative reconstruction algorithm (4 iterations, 32 subsets). After [18F]Florbetaben injection, subjects were allowed to wait for 90 min, and 47-slice images were acquired over 20 min. The injected dose was 300 MBq for every subject.

Image analysis

[18F]Florbetaben images were co-registered and re-sliced into individual T1 reference images using Statistical Parametric Mapping (SPM) 12 (Wellcome Trust Centre for Neuroimaging) software based on MATLAB (The MathWorks, Inc., Natick, MA, USA). All T1 reference images were segmented into the grey matter (GM) and WMH tissue classes using the unified segmentation algorithm of SPM12. The resultant probabilistic GM density map for each participant had a threshold of 0.5 applied to it, and a binary GM mask was thus created (0, no tissue; 1, tissue with a >50% probability of belonging to GM). The inverse nonlinear transformation parameter file from the segmentation algorithm of SPM12 was used to warp a simplified digital probabilistic atlas using automated anatomical labeling,15 consisting of 120 cortical and subcortical regions, into each participant’s native T1 space. These atlases were multiplied by the corresponding binary GM mask, which generated a GM-specific digital atlas for each participant. Raw,
co-registered, and re-sliced PET and MRI data for each participant were sampled using the same individual digital atlases created previously. The mean regional standardized uptake value ratios (SUVRs) were measured for each atlas region using this method. Regional amyloid binding ratios were acquired by dividing each atlas region by the respective mean cerebellar GM values. The mean cortical Aβ burden was expressed as the average SUVR of the area-weighted mean of the frontal, medial temporal, lateral temporal, lateral parietal, posterior cingulate-precuneus, basal ganglia, and occipital regions, which were also defined as ROIs for the exploratory first step partial correlation analyses.

**Statistical analysis**
Statistical analyses were performed using SPSS Version 22.0 (Statistical Package for the Social Sciences; IBM Co., Armonk, NY, USA).

| Table 1. Demographic and neuropsychological test performance for MCI subjects by conversion status |
|---------------------------------|---------------------------------|-----------------|
|                                | MCI non-converters (N=58) | MCI converters (N=17) | p value |
| Age (yr)                        | 73.2±6.7                    | 75.0±7.5             | 0.351   |
| Sex, female (%)                 | 56.9                        | 29.4                 | 0.046*  |
| Education (yr)                  | 9.3±4.4                     | 9.4±5.1              | 0.941   |
| Mean cortical amyloid burden    | 1.25±0.16                   | 1.38±0.27            | 0.079   |
| CDR                             | 0.5                         | 0.5                  |         |
| SMC                             | 5.1±3.1                     | 5.7±3.4              | 0.510   |
| GDS                             | 10.1±7.7                    | 9.7±7.3              | 0.850   |
| APOE e4 allele positive (%)     | 37.5                        | 29.3                 | 0.531   |
| MMSE                            | -1.20±1.48                  | -1.55±1.12           | 0.376   |
| Attention                       |                             |                      |         |
| DSF                             | -0.50±0.78                  | -0.47±0.91           | 0.903   |
| DSB                             | -0.48±0.82                  | -0.59±0.95           | 0.640   |
| Language                        |                             |                      |         |
| BNT                             | -0.36±0.98                  | -1.19±1.00           | 0.003*  |
| Visuospatial functions          |                             |                      |         |
| RCFT copy                       | -0.26±1.25                  | -1.28±2.40           | 0.101   |
| Memory                          |                             |                      |         |
| SVLTirl                         | -0.79±0.96                  | -1.18±0.82           | 0.134   |
| SVLTdrl                         | -1.13±1.08                  | -1.78±0.76           | 0.023*  |
| SVLTirc                         | -0.90±1.25                  | -1.17±0.82           | 0.291   |
| RCFTirl                         | -0.77±0.84                  | -1.06±1.12           | 0.251   |
| RCFTdrl                         | -0.77±0.82                  | -1.46±1.07           | 0.006*  |
| RCFTirc                         | -0.59±1.07                  | -0.94±1.40           | 0.265   |
| Executive functions             |                             |                      |         |
| Fluency_A                       | -0.68±0.96                  | -1.07±0.68           | 0.122   |
| Fluency_S                       | -0.83±0.77                  | -1.19±0.39           | 0.215   |
| Stroop Word                     | -0.41±1.14                  | -0.47±0.95           | 0.863   |
| Stroop Color Word               | -0.75±1.17                  | -1.74±1.67           | 0.007*  |
| TMT_A                           | -0.71±1.48                  | -1.36±2.12           | 0.154   |
| TMT_B                           | -0.53±1.13                  | -0.54±1.14           | 0.967   |

Values are presented as mean±SD. Neuropsychological data presented as group mean z-scores based on age-, education-, and sex specific normative information (SD). *significant at p<0.05 for unpaired T or chi-square tests. CDR, Clinical Dementia Rating; SMC, Subjective Memory Complaints; GDS, Geriatric Depression Scale; APOE, apolipoprotein; MMSE, Mini-Mental Status Examination; DSF, Digit Span Forward; DSB, Digit Span Backward; BNT, Boston Naming Test; RCFT, Rey Complex Figure Test; SVLT, Seoul Verbal Learning Test, immediate recall score; SVLTdrl, SVLT 20-minute delayed recall; RCFTdrl, RCFT immediate recall; SVLTirc, SVLT yes-no recognition score; RCFTirc, RCFT yes-no recognition score; fluency_A, fluency score for animal; fluency_S, fluency score for supermarket list; Stroop Color Word, Stroop score for color naming in color-word in incongruent condition; TMT, Trail Making Test; MCI, mild cognitive impairment; SD, standard deviation
NY, USA) and R statistical software version 3.3.3 (R Project for Statistical Computing, Vienna, Austria) within RStudio. Demographic and clinical data from the two groups (converter and non-converter) were compared using an unpaired t-test, while the χ² test was applied to compare proportions and categorical data. We assessed the effect of each biomarker variable with baseline mean cortical amyloid SUVRs and longitudinal mean cortical amyloid SUVR changes on time to a diagnosis of AD among subjects diagnosed with MCI at baseline using the Cox proportional hazards models that included age, sex, education, and apolipoprotein (APOE) e4 allele as adjustment covariates. The baseline visit was considered to be time zero. The longitudinal amyloid burden changes were defined as the last follow-up mean cortical SUVR minus the baseline mean cortical SUVR.

The AD prediction classification accuracy of the resulting models was calculated using receiver operating characteristic (ROC) curve analysis. The resulting models had baseline amyloid burden and longitudinal amyloid burden changes for MCI conversion prediction. Pairwise ROC curve comparisons for AD prediction models between baseline amyloid burden and longitudinal amyloid burden changes were calculated using the DeLong method.17 All ROC analyses were performed also for two subgroups of individuals with a follow-up duration of less than 24 months and participants with a follow-up duration of 24 months or more.

RESULTS

Participants

Seventy-five MCI subjects were examined using annual follow-up diagnosis. Of the 75 MCI participants, 17 (22.7% total, or an annual rate of 11.4%) converted to AD. The mean follow-up duration was 24 months (standard deviation [SD]=9.3; range, 11.6–42.0). Of the 75 MCI participants, 63 underwent second or/and third amyloid PET and MRI for follow-up. Clinical evaluations were performed within 1 month of amyloid PET and MRI. Of 63 MCI patients, 11 converted to AD dementia and 22 remained MCI at the second amyloid PET, and 6 converted to AD dementia and 24 remained MCI at the third amyloid PET.

Table 1 summarizes the demographic information and clinical manifestations for baseline measurements for MCI converter and non-converter groups. MCI converters did not show statistically significant differences in terms of age, education, mean cortical amyloid burden, CDR, Subjective Memory Complaints, Geriatric Depression Scale, and APOE e4 allele ratios, compared to MCI non-converters. However, MCI converters had significantly lower female frequency than MCI non-converters (29.4% vs. 56.9%, p=0.046). Furthermore, MCI converters had significantly lower z-scores than MCI non-converters in the BNT (p=0.003), SVLTdrl (p=0.023), RCFTdrl (p=0.006), and Stroop Color Word test (p=0.007).

Diagnostic changes during follow up

Table 2 summarizes the clinical diagnostic changes in baseline MCI during follow-up. Of these, 28 (37.3%) had stable aMCI diagnoses (from aMCI to aMCI), nine (12%) had stable naMCI (from naMCI to naMCI), 15 (20.0%) interchanged between aMCI and naMCI, 12 aMCI patients converted to AD (16.0%), five naMCI converted to AD (6.7%), five aMCI reverted to CN (6.7%) and one naMCI reverted to CN (1.3%). Patients in the two aMCI and naMCI to AD conversion groups were defined as MCI converters (n=17), and the other six groups were categorized as MCI non-converters (n=58).

Longitudinal amyloid burden changes during follow up

Table 2. Clinical diagnostic changes of MCI for two years follow-up

| Baseline diagnosis | Follow-up diagnosis | Number | Percentage |
|--------------------|---------------------|--------|------------|
| aMCI               | aMCI               | 28     | 37.3       |
| aMCI               | naMCI              | 11     | 14.7       |
| aMCI               | CN                 | 5      | 6.7        |
| aMCI               | AD                 | 12     | 16.0       |
| naMCI              | aMCI               | 4      | 5.3        |
| naMCI              | naMCI              | 9      | 12.0       |
| naMCI              | CN                 | 1      | 1.3        |
| naMCI              | AD                 | 5      | 6.7        |

MCI, mild cognitive impairment; aMCI, amnestic MCI; naMCI, nonamnestic MCI; CN, cognitively normal; AD, Alzheimer’s disease

Figure 1. Amyloid accumulation plot of the absolute change in standardized uptake value ratio (SUVR) in time, coded for whether subjects were classified as converters (orange) or non-converters (blue).
Baseline MCI Amyloid Burden and AD Progression

second follow-up subjects (n=33 and n=30), follow-up duration means were 16.3 and 32.3 months (SD, 6.7 and 4.8). Until last image follow-up with clinical diagnosis, mean amyloid burden change (follow-up SUVR–baseline SUVR) was -0.011 (SD, 0.16; range, -1.10–0.29).

Cox proportional hazards models with conversion to Alzheimer’s disease as the outcome measures

The age, sex, education, and APOE ε4 allele-adjusted HR for baseline mean cortical amyloid burden was 10.1 (p=0.04; 95% confidence interval [CI], 1.15–85.39) (Table 3). The age, sex, education, APOE ε4 allele, and baseline mean cortical amyloid burden adjusted hazard ratio (HR) for longitudinal amyloid burden changes was 0.2 (p=0.07; 95% CI, 0.02–1.18) (Table 4).

Receiver operating characteristic curve analysis of mild cognitive impairment conversion to Alzheimer’s disease prediction models

Mild cognitive impairment conversion to Alzheimer’s disease prediction models based on baseline amyloid burden

The MCI conversion to AD prediction model for the baseline amyloid burden showed that the overall ROC accuracy was 59.6% (95% CI, 40.3–79.0). For individuals with a follow-up duration of less than 24 months, the overall ROC accuracy was 71.1% (95% CI, 47.3–95.0). For participants with a follow-up duration of 24 months or more, the overall ROC accuracy was 58.3% (95% CI, 27.1–89.6) (Figure 2).

Mild cognitive impairment conversion to Alzheimer’s disease prediction models by longitudinal amyloid burden changes

The MCI conversion to AD prediction model for the longitudinal amyloid burden changes showed that the overall ROC accuracy was 65.2% (95% CI, 48.4–82.0). For individuals with a follow-up duration of less than 24 months, the overall ROC accuracy was 75.5% (95% CI, 53.9–97.1). For participants with a follow-up duration of 24 months or more, the overall ROC accuracy was 52.4% (95% CI, 30.5–74.3) (Figure 3).

Comparisons of the mild cognitive impairment conversion to Alzheimer’s disease prediction between baseline amyloid burden and longitudinal amyloid burden changes

Pairwise ROC curve comparisons for AD prediction models between baseline amyloid burden and longitudinal amyloid burden changes showed no significant area under the curve difference for all MCI participants (p=0.663). For participants with a follow-up duration of fewer than 24 months

---

Table 3. Baseline factors of Alzheimer’s disease prediction in mild cognitive impairment analyzed by Cox proportional hazards model

| HR       | 95% CI          | p    |
|----------|-----------------|------|
| Baseline mean cortical amyloid burden | 9.896 | 1.147–85.392 | 0.037 |
| Age      | 1.054 | 0.973–1.141 | 0.199 |
| Sex      | 2.451 | 0.727–8.267 | 0.148 |
| Education | 0.974  | 0.855–1.111 | 0.697 |
| Apolipoprotein | 1.566   | 0.506–4.851 | 0.437 |

Table 4. Longitudinal factors of Alzheimer’s disease prediction in mild cognitive impairment analyzed by Cox proportional hazards model

| HR       | 95% CI          | p    |
|----------|-----------------|------|
| Longitudinal amyloid burden changes | 0.164 | 0.023–1.177 | 0.072 |
| Baseline mean cortical amyloid burden | 8.649 | 0.990–75.559 | 0.051 |
| Age      | 1.036 | 0.956–1.123 | 0.388 |
| Sex      | 2.012 | 0.589–6.875 | 0.265 |
| Education | 0.999  | 0.869–1.150 | 0.994 |
| Apolipoprotein | 1.693   | 0.527–5.436 | 0.377 |

---

Figure 2. ROC curves for MCI conversion to Alzheimer’s disease prediction models by baseline mean cortical amyloid burden. ROC curves for total MCI individuals (black line), ROC curves for individuals with less than 24 months follow-up duration (red line), ROC curves for individuals with 24 months or more follow-up duration (blue line). ROC, receiver operating characteristic; MCI, mild cognitive impairment.
In the present study, we showed that an MCI conversion to AD prediction model based on the baseline amyloid burden had a 59.6% classification accuracy and that the longitudinal amyloid burden changes had a 65.2% classification accuracy. In our study, the AD progression rate of amyloid-positive individuals with MCI was lower than that reported previously. Previous studies calculating the baseline amyloid burden have reported that 67%–82% of amyloid-positive participants with MCI progressed to AD in about 32 months.2-4,7,8 However, the AD progression rate in the present study was 44%, although the mean follow-up duration was 24 months. This difference might be because we recruited individuals with MCI in the community, while previous studies were conducted in hospitals or private clinics. Of note, the present study had a baseline amyloid burden positive rate of 24% of total MCI subjects, compared with rates of 55%–69% found in hospital or clinic-based studies. Another reason might be that our study showed no significant amyloid SUVR difference at baseline between MCI converters and MCI non-converters, in contrast to previous studies reporting that MCI converters had significantly higher amyloid SUVR at baseline than MCI non-converters.2,7,8 In addition, follow-up diagnostic changes in the present study showed that 76% of MCI patients had a stable diagnosis 2 or 3 years later, although 20% of them had minor diagnostic interchanges between aMCI and naMCI, and 8% MCI reverted back to cognitively normal. These diagnostic changes are in line with the community vs. clinic comparison MCI study.16 Therefore, our study results could represent an AD progression model in the community of individuals with MCI.

The findings of the Cox proportional hazard model analysis showed that the HR for baseline mean cortical amyloid burden was 10.1 with statistical significance, the longitudinal amyloid burden changes was not significant. Pairwise comparisons of ROC curves showed that the longitudinal amyloid change model had a higher accuracy than the baseline amyloid model, in which statistical significance was not found. The different results between two analyses might be in that Cox proportional hazard model analysis adjusted age, sex, education, and APOE ε4 allele, but ROC curve analysis did not.

We believe that this might be the first study to demonstrate the ROC curve comparisons between the baseline amyloid model and longitudinal amyloid change model for MCI conversion to AD. Some studies have performed annual amyloid PET and diagnostic evaluation for the prediction of MCI conversion to AD.6,7,9,19,20 However, they included a relatively small sample of 10–48 individuals with MCI, and did not apply the longitudinal amyloid burden change to assess the prediction of MCI conversion to AD. One study reported that the amyloid burden increase was 7%–62% at 5 years, with a mean of 26% (annual 5%), although some individuals showed a slight decrease.6 Other large sample multicenter studies focused on longitudinal amyloid accumulation in cognitively normal or subtle cognitive decline individuals rather than MCI conversion to AD.21-24 They demonstrated that the increase in beta-amyloid deposition is faster in the predementia stage, but not at a constant rate across the clinical stages of the AD spectrum. These variations in the serial amyloid burden change are in line with our findings of no significant difference between the baseline and the longitudinal amyloid burden change for the prediction of MCI conversion to AD.

Our study had several limitations. Firstly, we had a relatively short follow-up duration of a mean of 24 months and follow-up times variations between subjects, although one longitudinal follow-up study reported that MCI patients were diagnosed with AD on average at the 3-year clinical follow-up visit.12 Thus, our results need to be supported with 3- or 5-year follow-up to confirm MCI conversion to AD prediction with serial amyloid changes. Second, our study included both aMCI and naMCI, which might have different progression rates.

**DISCUSSION**

In the present study, we showed that an MCI conversion to AD prediction model based on the baseline amyloid burden had a 59.6% classification accuracy and that the longitudinal amyloid burden changes had a 65.2% classification accuracy.

In our study, the AD progression rate of amyloid-positive individuals with MCI was lower than that reported previously. Previous studies calculating the baseline amyloid burden have reported that 67%–82% of amyloid-positive participants with MCI progressed to AD in about 32 months.2-4,7,8 However, the AD progression rate in the present study was 44%, although the mean follow-up duration was 24 months. This difference might be because we recruited individuals with MCI in the community, while previous studies were conducted in hospitals or private clinics. Of note, the present study had a baseline amyloid burden positive rate of 24% of total MCI subjects, compared with rates of 55%–69% found in hospital or clinic-based studies. Another reason might be that our study showed no significant amyloid SUVR difference at baseline between MCI converters and MCI non-converters, in contrast to previous studies reporting that MCI converters had significantly higher amyloid SUVR at baseline than MCI non-converters.2,7,8 In addition, follow-up diagnostic changes in the present study showed that 76% of MCI patients had a stable diagnosis 2 or 3 years later, although 20% of them had minor diagnostic interchanges between aMCI and naMCI, and 8% MCI reverted back to cognitively normal. These diagnostic changes are in line with the community vs. clinic comparison MCI study.16 Therefore, our study results could represent an AD progression model in the community of individuals with MCI.

The findings of the Cox proportional hazard model analysis showed that the HR for baseline mean cortical amyloid burden was 10.1 with statistical significance, the longitudinal amyloid burden changes was not significant. Pairwise comparisons of ROC curves showed that the longitudinal amyloid change model had a higher accuracy than the baseline amyloid model, in which statistical significance was not found. The different results between two analyses might be in that Cox proportional hazard model analysis adjusted age, sex, education, and APOE ε4 allele, but ROC curve analysis did not.

We believe that this might be the first study to demonstrate the ROC curve comparisons between the baseline amyloid model and longitudinal amyloid change model for MCI conversion to AD. Some studies have performed annual amyloid PET and diagnostic evaluation for the prediction of MCI conversion to AD.6,7,9,19,20 However, they included a relatively small sample of 10–48 individuals with MCI, and did not apply the longitudinal amyloid burden change to assess the prediction of MCI conversion to AD. One study reported that the amyloid burden increase was 7%–62% at 5 years, with a mean of 26% (annual 5%), although some individuals showed a slight decrease.6 Other large sample multicenter studies focused on longitudinal amyloid accumulation in cognitively normal or subtle cognitive decline individuals rather than MCI conversion to AD.21-24 They demonstrated that the increase in beta-amyloid deposition is faster in the predementia stage, but not at a constant rate across the clinical stages of the AD spectrum. These variations in the serial amyloid burden change are in line with our findings of no significant difference between the baseline and the longitudinal amyloid burden change for the prediction of MCI conversion to AD.

Our study had several limitations. Firstly, we had a relatively short follow-up duration of a mean of 24 months and follow-up times variations between subjects, although one longitudinal follow-up study reported that MCI patients were diagnosed with AD on average at the 3-year clinical follow-up visit.12 Thus, our results need to be supported with 3- or 5-year follow-up to confirm MCI conversion to AD prediction with serial amyloid changes. Second, our study included both aMCI and naMCI, which might have different progression rates.
Further, in our observations, we only included participants with MCI and amyloid PET. However, future studies need to include more individuals across the categories of cognitively normal, MCI, and mild AD dementia, as well as tau PET. Nevertheless, the results of the present study suggest that a single baseline amyloid burden could be sufficient in the prediction of AD conversion in MCI.

Availability of Data and Material

The datasets generated or analyzed during the study are available from the corresponding author on reasonable request.

Conflicts of Interest

II. Han Choo, a contributing editor of the Psychiatry Investigation, was not involved in the editorial evaluation or decision to publish this article. All remaining authors have declared no conflicts of interest.

Author Contributions

Conceptualization: IL Han Choo. Data curation: all authors. Formal analysis: II. Han Choo. Funding acquisition: all authors. Project administration: II. Han Choo, Hoowon Kim. Visualization: Yu Yong Choi. Writing—original draft: II. Han Choo. Writing—review & editing: II. Han Choo.

ORCID iDs

II. Han Choo https://orcid.org/0000-0001-6547-9735
Ari Chong https://orcid.org/0000-0001-9327-9810
Ji Yeon Chung https://orcid.org/0000-0002-4596-6613
Jung-Min Ha https://orcid.org/0000-0002-6932-8659
Yu Yong Choi https://orcid.org/0000-0001-8638-564X
Hoowon Kim https://orcid.org/0000-0001-5973-0559

Funding Statement

This study was funded by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MSIT) (No. 2016M3A9E9941914).

REFERENCES

1. Petersen RC. Mild cognitive impairment: transition between aging and Alzheimer's disease. Neurology 2000;15:93-101.
2. Okello A, Koivunen J, Edisson P, Archer HA, Turkheimer FE, Nägren K, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PET study. Neurology 2009;73:754-760.
3. Nordberg A, Carter SF, Rinne J, Drzezga A, Brooks DJ, Vandenberghe R, et al. A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging 2013;40:104-114.
4. Rowe CC, Bourgeat P, Ellis KA, Brown B, Lim YW, Mulligan R, et al. Predicting Alzheimer disease with β-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing. Ann Neurol 2013;74:905-913.
5. Villedrome VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvador O, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013;12:357-367.
6. Kemppainen NM, Scheinin NM, Koivunen J, Johansson J, Toivonen JT, Nägren K, et al. Five-year follow-up of 11C-PET uptake in Alzheimer's disease and MCI. Eur J Nucl Med Mol Imaging 2014;41:283-289.
7. Ong KT, Villedrome VL, Bahar-Fuchs A, Lamb F, Langdon N, Catafau AM, et al. Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study. J Neurol Neurosurg Psychiatry 2015;86:431-436.
8. Hataihata S, Wakebe D. Amyloid-β deposition and long-term progression in mild cognitive impairment due to Alzheimer's disease defined with amyloid PET imaging. J Alzheimers Dis 2017;57:765-773.
9. Hataihata S, Wakebe D, Ikuchi Y, Ichijo A. Longitudinal assessment of amyloid-β deposition by [18F]-flutemetamol PET imaging compared with [11C]-PIB across the spectrum of Alzheimer's disease. Front Aging Neurosci 2019;11:251.
10. Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414.
11. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183-194.
12. Fazekas F, Chawlk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol 1987;149:351-356.
13. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263-269.
14. Kang JW, Beom IG, Cho JY, Son HR. Accuracy of Korean-mini-mental status examination based on Seoul neuro-psychological screening battery II results. Korean J Fam Med 2016;37:177-181.
15. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomic parcellation of the MNI MRI single-subject brain. Neuroimage 2002;15:273-289.
16. Reiman EM, Chen K, Liu X, Bundy D, Yu M, Lee W, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 2009;106:6820-6825.
17. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-845.
18. Farias ST, Mungas D, Reed BR, Harvey D, DeCarli C. Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts. Arch Neurol 2009;66:1151-1157.
19. Iaccarino L, Chiotis K, Alongi P, Almkvist O, Wall A, Cerami C, et al. A cross-validation of FDG-and amyloid-PET biomarkers in mild cognitive impairment for the risk prediction to dementia due to Alzheimer's disease in a clinical setting. J Alzheimers Dis 2017;59:603-614.
20. Ye BS, Kim HJ, Kim YJ, Jung NY, Lee JS, Lee J, et al. Longitudinal outcomes of amyloid positive versus negative amnestic mild cognitive impairments: a three-year longitudinal study. Sci Rep 2018;8:5357.
21. Palmqvist S, Schön M, Strandberg O, Mattsson N, Stomrud E, Zetterberg H, et al. Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat Commun 2017;8:1214.
22. Colli JL, Heeman F, Salvador G, Ingala S, Altomare D, de Wilde A, et al. Multitracer model for staging cortical amyloid deposition using PET imaging. Neurology 2020;95:e1538-e1553.
23. Thomas KR, Bangen KJ, Weigand AJ, Edmonds EC, Wong CG, Cooper S, et al. Objective subtle cognitive difficulties predict future amyloid accumulation and neurodegeneration. Neurology 2020;94:e397-e406.
24. Lopes Alves I, Heeman F, Colli JL, Salvador G, Tolboom N, Vilot-Tejedor N, et al. Strategies to reduce sample sizes in Alzheimer's disease primary and secondary prevention trials using longitudinal amyloid PET imaging. Alzheimers Res Ther 2021;13:82.